Intravitreal triamcinolone acetonide (IVTA) has increasingly been employed as a treatment for various intraocular inflammatory, neovascular, exudative, proliferative, and oedematous conditions.^{1–4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46} The injection usually results in transient improvement in visual acuity but repeated injections are usually required because the vision increases and eventually decreases again.^{8,9,10,19,21,43,45}

Repeated IVTA injections have sparked investigations into the both dose response and quantification of the post-IVTA intraocular pressure rise.^12,39,42,43 Although 4–8 mg doses drawn undiluted from the commercially available vial are commonly used, some investigators wash the diluent from the commercially available medication and concentrate it into a 20–25 mg dose in a small volume.^{10–12,16,21–24,39,40,42–46} In terms of the duration of the IVTA effect …